Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813

Pharmacology Research and Perspectives

Volumn 3, Issue 2, 2015, Pages 1-14

  Lavreysen, Hilde ^a   Langlois, Xavier ^a   Donck, Luc Ver ^a   Nuñez, José María Cid ^a   Pype, Stefan ^a   Lütjens, Robert ^b   Megens, Anton ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Addex Therapeutics Plan les Ouates Switzerland   (Switzerland)

Author keywords

5HT2A receptor antagonist; Antipsychotic like activity; JNJ 40411813; JNJ 42153605; LY404039; MGlu2; PAM; Ritanserin

Indexed keywords

1 BUTYL 3 CHLORO 4 (4 PHENYLPIPERIDIN 1 YL) PYRIDIN 2(1H) ONE; 3 (CYCLOPROPYLMETHYL) 7 (4 PHENYLPIPERIDIN 1 YL) 8 (TRIFLUOROMETHYL)[ 1,2,4]TRIAZOLO[4,3 A]PYRIDINE; 4 AMINO 2 THIABICYCLO HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; DEXAMPHETAMINE; MEMANTINE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR AGONIST; RITANSERIN; SCOPOLAMINE; SEROTONIN 1A ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDITORY RESPONSE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG POTENTIATION; EXPERIMENTAL HYPERACTIVITY; HEAD TWITCH; IC50; LOCOMOTION; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; ROTAROD TEST; SCHIZOPHRENIA;

EID: 85007148366     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.97     Document Type: Article

References (48)

1. Aghajanian GK (2009). Modeling "psychosis" in vitro by inducing disordered neuronal network activity in cortical brain slices. Psychopharmacology 206: 575-585.
2. Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, Sanders-Bush E (2007). A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol 72: 477-484.
3. Cartmell J, Schoepp DD (2000). Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75: 889-907.
4. Castagne V, Moser PC, Porsolt RD (2009). Preclinical behavioral models for predicting antipsychotic activity. Adv Pharmacol 57: 381-418.
5. Cid JM, Tresadern G, Vega JA, de Lucas AI, Matesanz E, Iturrino L, et al. (2012). Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1, 2, 4]triazolo[4, 3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. J Med Chem 55: 8770-8789.
6. Conn PJ, Jones CK (2009). Promise of mGluR2/3 activators in psychiatry. Neuropsychopharmacology: official publication of the American College of. Neuropsychopharmacology 34: 248-249.
7. De Boer P, Sinha V, Hoeben E, Anghelescu I-G, Kezic I, Daly E, et al. (2013). Characterization of the clinical effect of a positive allosteric modulator of the metabotropic glutamate receptor-2. 68th Annual Scientific Convention of Society of Biological Psychiatry, May 16-18, 2013, San Francisco, CA.
8. Dedeurwaerdere S, Wintmolders C, Straetemans R, Pemberton D, Langlois X (2011). Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist. Psychopharmacology 214: 505-514.
9. Duncan GE, Leipzig JN, Mailman RB, Lieberman JA (1998a). Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 812: 65-75.
10. Duncan GE, Moy SS, Knapp DJ, Mueller RA, Breese GR (1998b). Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res 787: 181-190.
11. Fell MJ, Svensson KA, Johnson BG, Schoepp DD (2008). Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R, 4S, 5S, 6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4, 6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 326: 209-217.
12. Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R, et al. (2011). Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147: 1011-1023.
13. Galici R, Echemendia NG, Rodriguez AL, Conn PJ (2005). A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315: 1181-1187.
14. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, et al. (2006). Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318: 173-185.
15. Gewirtz JC, Marek GJ (2000). Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 23: 569-576.
16. Gleason SD, Shannon HE (1997). Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 129: 79-84.
17. Gonzalez-Maeso J, Sealfon SC (2009). Psychedelics and schizophrenia. Trends Neurosci 32: 225-232.
18. Hoeben E, Sinha V, de Boer P, Wuyts K, Bohets H, Scheers E, et al. 2013. Prediction of serotonin 2A receptor (5-HT2AR) occupancy in man from nonclinical pharmacology data. Exposure vs. 5-HT2AR occupancy modeling used to help design a positron emission tomography (PET) study in healthy male subjects. PAGE Meeting, 11-14 June 2013, Glasgow, UK.
19. Imre G (2007). The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268. CNS Drug Rev 13: 444-464.
20. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201-225.
21. Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, et al. (2005). Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology 179: 271-283.
22. Kent J, Anghelescu I, Kezic I, Daly E, Ceusters M, De Smedt H, et al. (2013). Safety, tolerability and potential therapeutic efficacy of a novel glutamate modulator as adjunctive treatment in patients with schizophrenia. 166th Annual Meeting of the American Psychiatric Association, 18-22 May 2013, San Francisco, CA.
23. Kent JM, Daly E, Ceusters M, Kezic I, Lane R, Lim P, et al. (2014). Efficacy and safety of a novel mGlu2 receptor positive allosteric modulator as an adjunctive treatment to an SSRI/SNRI in the treatment of anxious depression. 8th International meeting on metabotropic glutamate receptors, 28 September-3 October 2014, Taormina, Italy.
24. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, et al. (2011). A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 31: 349-355.
25. Klodzinska A, Bijak M, Tokarski K, Pilc A (2002). Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of in mice. Pharmacol Biochem Behav 73: 327-332.
26. 50) and its confidence interval, assuming a linear log dose-response function. Department of Global Medical and Scientific Information, Johnson & Johnson Pharmaceutical Research and Development, Janssen Pharmaceutica, Turnhoutseweg 30, B-2340 Beerse, Belgium. Internal Report N123705/1.
27. Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H (2010). Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol 77: 317-326.
28. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE (2013). Glutamate in schizophrenia: a focused review and meta-analysis of (1)H-MRS studies. Schizophr Bull 39: 120-129.
29. Megens AA, Hendrickx HM, Hens KA, Talloen WJ, Lavreysen H (2014). mGlu receptor-mediated modulation of conditioned avoidance behavior in rats. Eur J Pharmacol 727C: 130-139.
30. Miyamoto S, Leipzig JN, Lieberman JA, Duncan GE (2000). Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsychopharmacology 22: 400-412.
31. Moghaddam B, Adams BW (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281: 1349-1352.
32. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13: 1102-1107.
33. Paxinos G, Franklin K, 2001, eds. The mouse brain in stereotaxic coordinates. Academic Press, San Diego, CA.
34. Rorick-Kehn LM, Perkins EJ, Knitowski KM, Hart JC, Johnson BG, Schoepp DD, et al. (2006). Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. J Pharmacol Exp Ther 316: 905-913.
35. Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, et al. (2007a). In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology 193: 121-136.
36. Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, et al. (2007b). Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist. In vitro characterization of agonist (_)-(1R, 4S, 5S, 6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4, 6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 321: 308-317.
37. Schlumberger C, Pietraszek M, Gravius A, Danysz W (2010). Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia. Pharmacol Biochem Behav 95: 23-30.
38. Stauffer VL, Millen BA, Andersen S, Kinon BJ, Lagrandeur L, Lindenmayer JP, et al. (2013). Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res 150: 434-441.
39. te Riele P, Biesmans I, Peeters L, Lavreysen H, Langlois X, 2014, Characterization of the mGlu2 PAM radioligand [3H]JNJ-46281222 and its application for ex vivo receptor occupancy in rat brain. Poster presented at 8th international meeting on metabotropic glutamate receptors. Taormina, Sicily Italy, Sept 30, 2014.
40. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, et al. (2002). Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 159: 1944-1946.
41. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N, et al. (2003). Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 160: 2231-2233.
42. Trabanco AA, Cid JM, Lavreysen H, Macdonald GJ, Tresadern G (2011). Progress in the developement of positive allosteric modulators of the metabotropic glutamate receptor 2. Curr Med Chem 18: 47-68.
43. Tsutakawa R, 1982, Statistical methods in bioassay. Estimation of relative potency from quantal responses. Pp. 236-243 in S Kotz and N. L. Johnson, eds. Encyclopedia of statistical sciences. Wiley, New York, NY.
44. Voleti B, Navarria A, Liu RJ, Banasr M, Li N, Terwilliger R, et al. (2013). Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry 74: 742-749.
45. Wadenberg ML (2010). Conditioned avoidance response in the development of new antipsychotics. Curr Pharm Des 16: 358-370.
46. Weinberger DR (2007). Schizophrenia drug says goodbye to dopamine. Nat Med 13: 1018-1019.
47. Woolley ML, Pemberton DJ, Bate S, Corti C, Jones DN (2008). The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology 196: 431-440.
48. Lavreysen H, Ahnaou A, Drinkenburg W, Langlois X, Mackie C, Pype S, Lütjens R, Le Poul E, Trabanco A, Cid Nuñez J. (submitted). Pharmacological and Pharmacokinetic Properties of JNJ-40411813, a PAM of the mGlu2 Receptor. Pharmacol Res Perspect DOI: 10.1002/prp2.96